A Loh, PY Boey & RS Loh Singapore National Eye Centre World Cornea Congress VI Boston, Massachusetts, April 7-9, 2010 The authors have no financial interests.

Slides:



Advertisements
Similar presentations
Conjunctival Squamous Cell Carcinoma with Massive Intraocular Invasion Fiona Roberts, Glasgow BAOP, Manchester 7-8 th April, 2011.
Advertisements

Allergic conjunctivitis
Experience With Microbial Keratitis After Boston Type I Keratoprosthesis Implantation Cornea & Anterior Segment Services, L V Prasad Eye Institute, Hyderabad,
17278 Prosthetic Replacement in Steven-Johnson Syndrome Varsha Rathi Somasheila I Murthy L V Prasad Eye Institute, Hyderabad, India The authors have no.
Amit Gupta, MS Swapnil M. Parchand, MBBS Jagat Ram, MS Arunaloke Chakrabarti, MD Amod Gupta, MS Advanced Eye Centre, Post Graduate Institute of Medical.
Sérgio Kwitko, Tiago Lansini, Andressa P Stolz, Diane R Marinho Authors have no financial interest in the subject matter of this poster.
The authors have no financial interests to disclose
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Corticosteroids to Treat Bacterial Keratitis Ray KJ, Srinivasan M, Mascarenhas.
Long term Follow-up of PK cases with herpetic Leukomas, treated with topical Acyclovir and steroids WORLD CORNEA CONGRESS VII 2015 Ramon Naranjo-Tackman,MD.
Conjunctiva.
Evaluation of Adjuvant Role of Amniotic Membrane Transplantation in Acute Stevens Johnson Syndrome With Medical Therapy in a Randomized Controlled Study.
ALLERGIC CONJUNCTIVITIS
Himanshu Matalia, MD1,2 Arokiaraj Vincent, MSc2 D Kamesh, MSc2
DR WEI BOON KHOR FRCSED, FAMS CONSULTANT CORNEA AND EXTERNAL EYE DISEASE SERVICE SINGAPORE NATIONAL EYE CENTRE I HAVE NO FINANCIAL INTERESTS IN THE SUBJECT.
Siamak Zarei-Ghanavati M.D., FICO
ALLERGIC CONJUNCTIVITIS
Long term ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children Asim Ali, MD, FRCSC Kamiar Mireskandari, MD,
Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano,
Copyright restrictions may apply Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related.
Mak KS, 1 Miller RC, 2 Krishnan S, 3 Laperriere N, 4 Micke O, 5 Rutten I, 6 Kadish SP, 7 Ozsahin M, 8 and Mirimanoff RO 8 1 Harvard Medical School, Boston,
Management of Methicillin- Resistant Staphylococcus Aureus Keratitis in Post-surgical Patients: Two Case Reports Sujata P. Prabhu, MD and Timothy Y. Chou,
Hemi-Automated Lamellar Keratoplasty (HALK) Leonard Yuen, MD MPH MRCOphth Jodhbir Mehta, FRCS FRCOphth Li Lim, FRCOphth Donald Tan, FRCS FRCOphth SINGAPORE.
Blepharitis and Dry eyes in Aromatase Inhibitor Users
Modified Postoperative Regimen to Increase Retention of Keratoprostheses Juan Carlos Abad, MD Private practice, Medellín - Colombia Carolina Gómez Calle,
Somasheila I. Murthy, Prashant Garg, Pravin K. Vaddavalli
Allergic eye disease Pammal Ashwin Sunil Shah 2008, Birmingham UK A seminar for a group of eye professionals Pictures from the www.
Case Analysis I- Lecture 4
Effects of Xalatan® (latanoprost) or Travatan® (travoprost) on Ocular Surface Signs and Symptoms in Ocular Hypertensive or Glaucoma Patients. M.B. McDonald1,
Dept. of Ophthalmology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. Outcome after big-bubble deep anterior lamellar keratoplasty.
BACTERIAL KERATITIS AND ASSOCIATED ENDOPHTHALMITIS Dermot Cassidy FRANZCO, Paul Connell FRCSI, Penelope Allen FRANZCO, Rasik Vajpayee MS, FRCS(Edin), FRANZCO.
The Red Eye Marc A. Booth, M.D. 10 April Objectives  Obtain a pertinent history for patients presenting with a red eye  Formulate a differential.
Topical Tacrolimus 0,03% for Treatment of Refractory Allergic Conjunctivitis Diane Marinho, Andréia Ferreira Laranjeira, Sérgio Kwitko, Samuel Rymer Hospital.
Table 2.1.1: New Transplant Rate per million population (pmp), Year New transplants
Ten-year Clinicopathological Review Of Ocular Surface Squamous Neoplasia In An Ophthalmological Center In Mexico City Lucero Pedro-Aguilar, M. D. Alvarez-Melloni.
Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano,
Restoration of vision after alkali burn in 11 year old boy
Management of Aniridic Keratopathy with Allograft Limbal Stem Cell Transplantation Followed by Phacoemulsification Surgery Sibel Aksoy, MD, Yonca A. Akova,
Evaluation of Systane® versus Placebo in Corneal Epithelial Healing Following Photorefractive Keratectomy (PRK) Lt Col Charles D. Reilly Major Vasudha.
CASE IV CORNEAL HYDROPS.
Glaucoma and Penetrating Keratoplasty : Incidence, Risk Factors, and Outcomes Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author.
OCULAR FEATURES OF VERNAL KERATOCONJUNCTIVITIS IN CHILDREN REQUIRING TRABECULECTOMY WITH MITOMYCIN-C FOR STEROID-INDUCED GLAUCOMA CORDELIA CHAN FRCSEd.
Modern clinical use of Mini- scleral contact lenses WCO VI – Boston Dr Langis Michaud OD M.SC. FAAO (Dipl) Associate Professor.
Prospective Correlation of Symptoms and Clinical Grading in Vernal Keratoconjunctivitis Patients Srikant K Sahu, Shraddha Pawan Sureka, Sujata Das, Apurva.
Combined Phacoemulsification and Ahmed Glaucoma Drainage Implant Surgery Leonidas Traipe, M.D. Felipe Valenzuela, M.D. Carlos Nieme, M.D Juan Stoppel,
Post Keratoplasty Atopic Sclerokeratitis (PKAS) after Deep Anterior Lamellar Keratoplasty (DALK). Sharmina R Khan William H Ayliffe Mayday University Hospital,
Severity of Herpes Zoster Ophthalmicus: Onset at Younger Than 60 Years Versus 60 Years or Older Neelofar Ghaznawi MD, Ajoy Virdi MD, Amir Dayan, Christopher.
WEILL.CORNELL.EDU Outcomes of Acute Interventions for SJS/TEN Using a Novel Grading Scale and Treatment Algorithm World Cornea Congress VII Jessica B.
Clinical outcome of DALK in Keratoconus – A one year follow up
Long-term outcomes of keratolimbal allografts and conjunctival limbal autografts for total limbal stem cell deficiency M. Ziaei MBChB (Hons), FRCOphth.
Mark Dacey MD, Brian Sullivan MD, and Steven Verity MD University of Texas Southwestern Medical Center and VA Medical Center, Dallas, TX None of the authors.
Topical Cyclosporine 0.05% as a Long-Term Monotherapy for Atopic Keratoconjunctivitis Jonathan H. Tzu, M.D ¹, * ; C. Asli Utine, M.D ¹,², * Michael Stern,
Comparison of Efficacy of 0.05% Cyclosporine Ophthalmic Emulsion
Corneal Tattooing with Amniotic Membrane Woo Chan Park M.D., Won Yeol Ryu M.D. Dept. of Ophthalmology, College of Medicine, Dong-A University Busan, Korea.
Title: Use of Topical Cyclosporine 0
Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,
Treatment of symptomatic bullous keratopathy with poor visual prognosis using a modified Gundersen conjunctival flap and amniotic membrane Jose L. Güell.
Elmira Baghdasaryan1,2, M.D. Sophie X. Deng1, M.D., Ph.D.
Yonca Aydin Akova MD, Leyla Erkanli Asena MD
Role of a Sutureless Amniotic Membrane Patch in Restoring the Corneal Surface Anterior Segment OCT Assessment Roxana Ursea, MD Matthew T. Feng, MD The.
Department of Cornea, Cataract & Refractive Surgery and *Ocular Microbiology Dr Rajendra Prasad Centre For Ophthalmic Sciences, AIIMS Dr. Manoj Sharma,
Date of download: 6/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Outcomes of Keratolimbal Allograft for Total.
Not Just for Dry Eyes Off Label Use of Cyclosporine
The Course of Dry Eye After Phacoemulsification Surgery Servet Cetinkaya 1, Emine Mestan 2, Nursen Oncel Acir 3, Yasemin Fatma Cetinkaya 4, Zeynep Dadaci.
Anita Panda Rakhi Kusumesh Murugesan Vanathi Tushar Agarwal S Khokhar Cornea and Refractive Surgery Services Dr Rajendra Prasad Centre for Ophthalmic Sciences.
Finger prick Autologous Blood (FAB) as a novel approach to treatment of non-healing corneal epithelial defects and dry eyes James R Wawrzynski, Jonathan.
The Authors have no financial interest
Dr. Sandeep Arora FRCS Dr Ashish Nagpal FRCS
Jodi Luchs, MD Carlos Buznego, MD William Trattler, MD
Allergic and immunologic disorders of the eye. Part II: Ocular allergy
Presentation transcript:

A Loh, PY Boey & RS Loh Singapore National Eye Centre World Cornea Congress VI Boston, Massachusetts, April 7-9, 2010 The authors have no financial interests in the subject matter of this poster

Introduction Atopic keratoconjunctivitis (AKC) is a bilateral, chronic inflammation of the conjunctiva and lids associated with atopic dermatitis There is a male preponderance, with the onset of disease typically in the second to fifth decade The major symptom is ocular itching which may be seasonal or perennial Signs include Lids eczema, blepharitis, meibomianitis & tarsal margin keratinization Conjunctivasub-epithelial fibrosis, symblepharon, fornix shortening & giant papillae Corneasuperficial punctate keratitis, neovascularization & persistent epithelial defects Shield ulcers, as defined as an epithelial defect with intact Bowman’s membrane and an overlying fibrin/mucous plaque, occurring in the superior half of the corneal surface is classically associated with Vernal keratoconjunctivitis (VKC) In this study we report the incidence of four cases of inferior shield ulcers occurring in atopic keratoconjunctivitis

Materials & Methods IRB review board approval Retrospective case series in one centre, CGH, from 01/01/05 to 30/12/08 The diagnosis was based on the history and presentation of ocular surface/corneal findings The following were assessed - Risk factors - Atopic dermatitis Asthma Allergic rhinitis Examination - Snellen visual acuity Slit-lamp examination Goldman tonometry

Results 27 patients (24 bilateral) with allergic ocular disease were identified in the 4 year study period AKC was present in 19 of these 27 patients (16 bilateral disease) Age at onset ranged from 10 to 30 years (mean 18.4 years, median 18). with a male:female ratio of 4.75:1 (females n=4, 21.1%). Racial preponderance - Chinese 74.9%(n=15) Malay 25.1%(n=4) Follow-up period ranged from 4 to 72 months (median 4 weeks) Average recurrence rate was 1 per 4.7 months Number of recurrences ranged from 0 to 5 (median 2)

Results Pre-existing disease at presentation Asthma 36.8% (n=7) Eczema63.2% (n=12) Allergic rhinitis42.1% (n=8) Family history of atopic disease was present in 31.6% (n=6) Symptoms on presentation Itch and redness were present in all patients Mucoid discharge 73.7% (n=14) Watering84.2% (n=16)

Results Visual acuity (VA) Best corrected VA (BCVA) ranged from 20/20 to 20/120 (median 20/30) with final VA on resolution of 20/20 or better. There was no loss in lines of BCVA. Minimum BCVA ranged from 20/20 to 20/200 (median 20/40) Slitlamp findings were as follows Giant papillae 68.4% (n=13) Limbal follicles 31.6% (n=6) Shield ulcers 31.6% (n=6) Corneal scars26.3% (n=5) Treatment All patients were treated with topical mast cell stabilizer/anti-histamine (eg. G Olopatadine 0.1%) and topical steroids (eg. Fluoromethalone 0.5%, Dexamethasone 0.3% and Prednisolone Acetate 1.0%) Six patients (31.6%) required topical Cyclosporine A (CSA) 0.5% for long term control There was no incidence of secondary cataract or glaucoma

Results Inferior shield ulcers occurred in 4 patients (21%). This was present in all cases in the left eye, with one having coincident upper shield ulcer in the fellow eye All patients were males, 3 were of Chinese and 1 of Malay racial origin. Age at presentation ranged from 12 to 19 years Pre-existing asthma, atopic disease and/or eczema was present in 3 patients Bilateral disease was present in 3 patients BCVA was 20/40 to 20/120 at presentation improving to 20/20 in all cases with treatment. All shield ulcers resolved within 4 weeks using a combination of topical Olopatadine 0.1% and Prednisolone Acetate 1.0%. Three patients required topical CSA 0.5% as maintenance therapy Giant papillae were present in 3 patients, with limbal follicles in one

Fig 1. Clinical patterns of inferior shield ulcers a & b – inferior shield with mucous plaque c & d – mucous plaque removed – epithelial defect revealed Fig 1aFig 1b Fig 1cFig 1d

Fig 2. Other features a – inferior pseudogerontoxon b – limbal follicles and meibomiatis c & d – early superior shield ulcer with inferior corneal scar from healed inferior shield ulcer Fig 2aFig 2b Fig 2c Fig 2d

Discussion This study demonstrates that inferior shield ulcers can occur in atopic eye disease The pathogenesis of inferior shield ulcers in VKC has been previously described by Buckley Inferior shield ulcers in AKC may be due to a combination of keratinization of the lid margins, meibomianitis and late presentation for treatment Visual prognosis in this study group is good The response to topical anti-histamine/mast cell stabilizers and steroid therapy combination was good although maintenance therapy with topical CSA 0.5% was required in 31% (n=6) of cases. This may partly explain the absence of secondary glaucoma References 1. Buckley RJ. Vernal keratoconjunctivitis. Int Ophthalmol Clin : Tuft SJ, Kemeny DM, Dart JK et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology Feb;98(2): Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology Aug;97(8): Hingorani M, Moodaley L, Calder VL et al. A randomized placebo controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology Sept;105(9): Anzaaf F, Gallagher MJ, Bhat P et al. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea 2008 Sep;27(8):884-8